This was discussed by Jon pilcher in the webinar I believe. His general response to this and similar questions was that they are not a priority. I think he also said ASD would not have an orphan drug status, so it would be more complicated, more timely and costly to bring to market. The indications currently being focused on are orphan drugs. They may look at other applications in the long term, but understandbly, this is not the focus in the short term.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$12.26 |
Change
-0.280(2.23%) |
Mkt cap ! $1.525B | |||
| Open | High | Low | Value | Volume |
| $12.45 | $12.45 | $11.88 | $6.952M | 570.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 231 | $12.26 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $12.32 | 1979 | 2 |
View Market Depth
| Last trade - 16.13pm 23/06/2025 (20 minute delay) ? |
| NEU (ASX) Chart |